Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Aug 6, 2022; 10(22): 7906-7912
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7906
Table 1 Timeline of the treatment process
Time
Symptom
Platelet counts
Treatment
Day 1Bloody sputum, scattered mottled, high-density shadows in both lungs140000/μLLatamoxef (dose: 2.0 g) intravenously Q12H
Day 9Chills and fever to 38.2 ℃ (18:00)44000/μL (8:00 am)-
Day 10Positive T SPOT-TB testing results-Added isoniazid tablets 0.3 g QD, rifampicin capsules 0.6 g QD
Day 11Secondary pulmonary tuberculosis, cervical lymph node tuberculosis, and splenic tuberculosis were confirmed-Continued adding pyrazinamide 0.5 g TID, ethambutol 1.0 g QD
Day 12Body temperature returned to normal but scattered purpura and ecchymosis appeared on his limbs and trunk's skin7000/μLReplaced rifampicin with levofloxacin; Added recombinant human thrombopoietin (15000 units/d), human immunoglobulin (20.0 g/d), 15 units platelets, and 5 mg dexamethasone
Day 13Hemoptysis44000/μLContinued adding tranexamic acid sodium chloride (0.5 g/d), etamsylate (2.0 g/d) and spearhead agkistrodon hemocoagulase (2.0 U/d) for hemostasis
Day 15Critical state9000/μLDiscontinued latamoxef 2.0 g Q12H and added vitamin K1 (10 mg/d)
Day 16-57000/μLDiscontinued the human immunoglobulin injection and recombinant human thrombopoietin
Day 17-157000/μLDiscontinued vitamin K1 and dexamethasone
Day 23-255000/μL-
Day 24Discharged-Took isoniazid, ethambutol, pyrazinamide, and levofloxacin for tuberculosis treatment
The 1, 3, 5 wk, and 15-mo after discharge-NormalTook isoniazid, ethambutol, pyrazinamide, and levofloxacin for tuberculosis treatment